Stereotaxis, Inc. (STXS)

NYSEAMERICAN: STXS · Real-Time Price · USD
2.200
-0.090 (-3.93%)
At close: Feb 21, 2025, 4:00 PM
2.180
-0.020 (-0.91%)
After-hours: Feb 21, 2025, 7:54 PM EST
-3.93%
Market Cap 185.56M
Revenue (ttm) 25.14M
Net Income (ttm) -22.89M
Shares Out 84.73M
EPS (ttm) -0.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 400,758
Open 2.320
Previous Close 2.290
Day's Range 2.180 - 2.320
52-Week Range 1.660 - 3.290
Beta 1.53
Analysts Strong Buy
Price Target 4.50 (+104.55%)
Earnings Date Mar 3, 2025

About STXS

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company provides Odyssey, a real-time information solution to manage,... [Read more]

Sector Healthcare
IPO Date Aug 12, 2004
Employees 122
Stock Exchange NYSEAMERICAN
Ticker Symbol STXS
Full Company Profile

Financial Performance

In 2023, Stereotaxis's revenue was $26.77 million, a decrease of -4.89% compared to the previous year's $28.15 million. Losses were -$22.06 million, 12.3% more than in 2022.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for STXS stock is "Strong Buy." The 12-month stock price forecast is $4.5, which is an increase of 104.55% from the latest price.

Price Target
$4.5
(104.55% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Stock Market Sleeps On Stereotaxis MAGiC CE Mark

Stereotaxis' MAGiC catheter received CE Mark approval in Europe, enabling the company to earn an additional $3k per procedure with +80% gross margins. FDA approval of MAGiC is expected by September. T...

7 days ago - Seeking Alpha

Stereotaxis to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

ST. LOUIS, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r...

18 days ago - GlobeNewsWire

Stereotaxis Announces First GenesisX Robotic System Order

ST. LOUIS, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has receive...

22 days ago - GlobeNewsWire

Stereotaxis Receives CE Mark Approval for the MAGiC Ablation Catheter

ST. LOUIS, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it receiv...

25 days ago - GlobeNewsWire

Oulu University Hospital Enhances Leadership in Arrhythmia Care with Advanced Genesis Robotic Technology

ST. LOUIS, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physician...

5 weeks ago - GlobeNewsWire

Magbot Robotic Magnetic Navigation Ablation Catheter Approved by China's NMPA

ST. LOUIS and SHANGHAI, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Shanghai MicroPort EP Medtech Co., Ltd. (688351.SH, “MicroPort EP”), today announced that the Magbot™ Magnetic Na...

2 months ago - GlobeNewsWire

Stereotaxis' GenesisX Robotic System to be Showcased for the First Time at RSNA 2024 by Neusoft Medical Systems

ST. LOUIS and SHENYANG, China, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Neusoft Medical Systems Co., Ltd (“Neusoft Medical Systems”) today announced that Stereotaxis' latest Gene...

2 months ago - GlobeNewsWire

Stereotaxis To Drive Transformational Growth Via Full Ecosystem Launch In 2025

MAGiC is set to receive the CE Mark by early 2025. Tenders will be completed by Q2 or Q3 2025; the FDA approval timeline is similar. The APT acquisition allowed Stereotaxis to complete the manufacturi...

2 months ago - Seeking Alpha

Stereotaxis to Participate in Piper Sandler 36th Annual Healthcare Conference

ST. LOUIS, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fis...

3 months ago - GlobeNewsWire

Stereotaxis Genesis Robotic System Achieves Regulatory Approval in China

ST. LOUIS and SHANGHAI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Shanghai MicroPort EP Medtech Co., Ltd. (688351.SH, “MicroPort EP”), today announced regulatory approval of the G...

3 months ago - GlobeNewsWire

Hospital Da Luz is the First in Portugal to Adopt Genesis Robotic System

ST. LOUIS, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physician...

3 months ago - GlobeNewsWire

Stereotaxis, Inc. (STXS) Q3 2024 Earnings Call Transcript

Stereotaxis, Inc. (NYSE:STXS) Q3 2024 Earnings Conference Call November 11, 2024 4:30 PM ET Company Participants David Fischel - Chairman and Chief Executive Officer Kimberly Peery - Chief Financial ...

3 months ago - Seeking Alpha

Stereotaxis Reports 2024 Third Quarter Financial Results

ST. LOUIS, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resul...

3 months ago - GlobeNewsWire

Stereotaxis Technology to be Featured at Annual Meeting of the Society for Cardiac Robotic Navigation

ST. LOUIS, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will p...

4 months ago - GlobeNewsWire

Stereotaxis to Present at Upcoming Investor Conferences

ST. LOUIS, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fi...

5 months ago - GlobeNewsWire

Stereotaxis Robotic Technology to be Featured during Heart Rhythm Society's HRX Congress

ST. LOUIS, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that its tech...

6 months ago - GlobeNewsWire

Stereotaxis Receives CE Mark For GenesisX, Nears MAGiC Approval

GenesisX was approved in Europe and is set to be approved in the US late this year. The new robot is a giant leap forward in accessibility. Stereotaxis should get MAGiC approved in Europe in October. ...

6 months ago - Seeking Alpha

Stereotaxis, Inc. (STXS) Q2 2024 Earnings Call Transcript

Stereotaxis, Inc. (NYSE:STXS) Q2 2024 Earnings Conference Call August 12, 2024 4:30 PM ET Company Participants David Fischel - Chairman and CEO Kimberly Peery - CFO Conference Call Participants Adam ...

6 months ago - Seeking Alpha

Stereotaxis Reports 2024 Second Quarter Financial Results

ST. LOUIS, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resul...

6 months ago - GlobeNewsWire

Stereotaxis Achieves CE Mark in Europe and Submits 510(k) in the US for Next Generation Robotic System GenesisX

Latest innovation in Robotic Magnetic Navigation technology supports broad accessibility of robotics for minimally-invasive endovascular surgery GenesisX has obtained CE mark in Europe and has been su...

6 months ago - GlobeNewsWire

Stereotaxis to Report Second Quarter 2024 Financial Results on August 12, 2024

ST. LOUIS, July 22, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r...

7 months ago - GlobeNewsWire

Stereotaxis Strengthens Board of Directors with Appointment of Nachum Shamir

ST. LOUIS, July 18, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced the appointment of Nachum “Homi”...

7 months ago - GlobeNewsWire

Penn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for Heart Treatment

ST. LOUIS, May 29, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announces the successful treatment of the f...

9 months ago - GlobeNewsWire

Stereotaxis Receives CE Mark Recertification Under EU's MDR Regulatory Framework

ST. LOUIS, May 24, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has rec...

9 months ago - GlobeNewsWire

Stereotaxis Makes A Strategic Acquisition Bolstering Its Future

Stereotaxis made a strategic acquisition of catheter company Access Point Technologies, which is expected to contribute $5 million in sales in the first 12 months after the acquisition. Access Point w...

9 months ago - Seeking Alpha